作者
Satoshi Noda, Tetsuya Yoshida, Daiki Hira, Ryosuke Murai, Keiji Tomita, Teruhiko Tsuru, Susumu Kageyama, Akihiro Kawauchi, Yoshito Ikeda, Shin-ya Morita, Tomohiro Terada
发表日期
2019/4/1
期刊
Clinical Genitourinary Cancer
卷号
17
期号
2
页码范围
e306-e313
出版商
Elsevier
简介
Background
Severe adverse events frequently occur in patients treated with pazopanib, necessitating dose reduction and discontinuation. However, information on the exposure-toxicity relationship is limited.
Patients and Methods
For this retrospective and observational clinical study, we examined 27 patients with renal cell carcinoma treated with pazopanib and enrolled between October 2014 and March 2018. The primary goal was to evaluate the association between trough pazopanib concentration and occurrence of grade ≥ 3 toxicities, and secondarily, to estimate the association between trough pazopanib concentration and objective response rate.
Results
Mean trough pazopanib concentration was significantly higher in the grade ≥ 3 toxicity group (n = 9) than in the grade ≤ 2 toxicity group (n = 18). Based on the receiver operating characteristic curve, the threshold value of trough pazopanib concentration for …
学术搜索中的文章
S Noda, T Yoshida, D Hira, R Murai, K Tomita, T Tsuru… - Clinical Genitourinary Cancer, 2019